Where could Allergan’s cost cuts fall? DTC spending, for starters

Bill Meury
Allergan commercial chief Bill Meury said Wednesday that social media could help make Allergan's DTC spending more efficient.

When Allergan CEO Brent Saunders announced Wednesday that cost cuts would come “rapidly,” he didn’t offer any insight as to where in the business those cuts would be. But commercial chief Bill Meury did.

Allergan’s investment level over the past year and a half or so has been “fairly high,” thanks to a dozen new products or indications. And “for some of those businesses, the investment level's got to be moderated,” Meury said on Allergan’s third-quarter earnings call.

One way the company might do it? Cutting back on DTC spending. “A big part of our DTC budget is national television advertising, and there are social media and other analytics techniques that are emerging, I think, that are going to allow us to do that a lot more efficiently,” Meury said, adding that “as efficiently as I think we run this operation, there's room to make some changes.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Cost cuts are coming for Allergan, CEO says. But a breakup isn’t

That’s not to say Allergan—one of the largest direct-to-consumer advertisers in the country, by Meury’s description—is backing away from DTC altogether.

The company’s CoolSculpting System, a contouring product picked up through Allergan’s Zeltiq acquisition, is exceeding expectations in the U.S. In response, Allergan has upped its DTC levels “to drive awareness and demand,” Meury said.

The Dublin drugmaker is also launching a nationwide DTC effort for antipsychotic Vraylar in bipolar mania. And DTC continues to play a role in Allergan’s efforts to help GI med Viberzi bounce back from a contraindication, Meury said.

RELATED: Allergan loses Restasis patent protections in federal court decision

But Allergan, which could soon see generic competition to second-best-seller Restasis after a recent patent ruling, needs to squeeze out savings somewhere, and Saunders assured investors it would happen in “a way that protects the long-term growth drivers.”

“That’s what we get paid for as management,” he said, adding that, “We need to manage this business to protect our shareholders while not sacrificing future growth.”

Suggested Articles

GSK has the strictest sales pay rules in the industry, but it's loosening up. It will now allow specialty salespeople to take home bigger paychecks.

Sarepta Therapeutics’ DMD therapy Exondys has already been knocked for its skimpy clinical data. Now a price watchdog says it’s also too expensive.

Rumor has it that several companies are in talks to buy Daiichi's over-the-counter drugs business, which could fetch $900 million.